Trial · NCT02750514
Adverse events4,407
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 4,407
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Track 1 - Nivolumab | 7 | 40 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 1 - Nivolumab + Dasatinib | 1 | 4 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 1 - Nivolumab + Ipilimumab | 0 | 3 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 2 - Nivolumab | 1 | 9 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 2 - Nivolumab + Dasatinib | 3 | 8 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 2 - Nivolumab + BMS986016 | 0 | 2 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 2 - Nivolumab + Ipilimumab | 3 | 12 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 3 - Nivolumab + Dasatinib | 6 | 41 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 3 - Nivolumab + BMS986016 | 2 | 16 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 3 - Nivolumab + Ipilimumab | 1 | 18 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 4 - Nivolumab + Dasatinib | 15 | 53 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 4 - Nivolumab + Ipilimumab | 10 | 60 | |
| other | Anaemia | Blood and lymphatic system disorders | Track 5 - Nivolumab + BMS986205 | 6 | 43 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Track 1 - Nivolumab | 1 | 40 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Track 1 - Nivolumab + Dasatinib | 0 | 4 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Track 1 - Nivolumab + Ipilimumab | 0 | 3 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Track 2 - Nivolumab | 0 | 9 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Track 2 - Nivolumab + Dasatinib | 0 | 8 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Track 2 - Nivolumab + BMS986016 | 0 | 2 | |
| other | Leukocytosis | Blood and lymphatic system disorders | Track 2 - Nivolumab + Ipilimumab | 0 | 12 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02750514/events